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Abstract 
 
Multidrug resistance (MDR) is a globally relevant problem that requires novel approaches. 
Two-component systems are a promising, yet untapped target for novel antibacterials. They are 
prevalent in bacteria and absent in mammals, and their activity can be modulated upon perception of 
various stimuli. Screening pre-existing compound libraries could reveal small molecules that inhibit 
stimulus-perception by virulence-modulating receptors, reduce signal output from essential receptors 
or identify artificial stimulatory ligands for novel SHKs that are involved in virulence. Those small 
molecules could possess desirable therapeutic properties to combat MDR. We propose that a modular 
screening platform in which the periplasmic domain of the targeted receptors are fused to the 
cytoplasmic domain of a well-characterized receptor that governs fluorescence reporter genes could 
be employed to rapidly screen currently existing small molecule libraries. Here, we have examined 
two previously created Tar-EnvZ chimeras and a novel NarX-EnvZ chimera. We demonstrate that it 
is possible to couple periplasmic stimulus-perceiving domains to an invariable cytoplasmic domain 
that governs transcription of a dynamic fluorescent reporter system. Furthermore, we show that 
aromatic tuning, or repositioning the aromatic residues at the end of the second transmembrane helix 
(TM2), modulates baseline signal output from the tested chimeras and even restores output from a 
non-functional NarX-EnvZ chimera. Finally, we observe an inverse correlation between baseline 
signal output and the degree of response to cognate stimuli. In summary, we propose that the platform 
described here, a fluorescent Escherichia coli reporter strain with plasmid-based expression of the 
aromatically tuned chimeric receptors, represents a synthetic biology approach to rapidly screen pre-
existing compound libraries for receptor-modulating activities. 
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Multidrug resistance (MDR) is a problem that is frequently associated with nosocomial 
infections and that limits therapeutic options.1 In Europe, infections with antibiotic-resistant bacteria 
kill nearly 25,000 patients annually and represents a total expenditure of approximately 1.5 billion 
€.2 The discovery and adaptation of traditional antibiotics has stagnated in recent decades. It is thus 
important to search for novel approaches to combat the growing danger of antibiotic resistance. 
Bacteria sense, respond and adapt to external stimuli via two-component signaling (TCS) 
circuits. The external stimuli comprise a wide range of environmental conditions including nutrient 
availability, ambient temperature or external osmolarity.3 Another purpose of TCSs is to facilitate 
multi-organism phenomena such as quorum sensing, biofilm formation and host-pathogen 
interaction.4 Most importantly, TCSs are widespread in bacteria but noticeably absent in mammals, 
which renders them excellent targets for novel antibacterials.5 
A canonical TCS consists of a membrane-spanning sensor histidine kinase (SHK) and a 
cytoplasmic response regulator (RR).3 The largest group of SHKs possesses a periplasmic or 
extracellular domain responsible for stimulus perception. Interaction with stimuli provokes 
subsequent signal transduction to the cell interior via conformational charges of the adjacent 
transmembrane domain.6 These conformational changes trigger autophosphorylation and subsequent 
phosphorylation of the RR. Within bifunctional SHKs, the extent of input stimulus controls the ratio 
of the kinase and phosphatase activities and thus governs the intracellular level of phosphorylated 
cognate RR.7 This phosphorylation, in turn, modulates the activity of the attached output domain, 
which interacts with DNA to control transcription of genes appropriate for mediating a response to 
the perceived stimulus.3 
Based on the conserved domain function of TCSs, two different classes of therapeutic targets 
have been proposed, each with its own supporting evidence.8 Several SHKs that regulate bacterial 
virulence and their respective cognate stimuli are known and a previous study suggests that SHK-
stimulus interactions can be disrupted.9 QseC is a canonical SHK found within at least 25 important 
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human and plant pathogens. Screening a library of 150,000 small organic molecules resulted in 
several hits that inhibited QseC-mediated expression of downstream virulence genes. The most 
promising of these compounds (LED209) was shown to reduce the efficiency of colonization by 
several QseC-containing pathogens in mice.9 A subsequent study employed structure-activity 
relationships (SAR) to identify several more effective derivatives of LED209.10 A similar approach 
led to a discovery of an inhibitor targeting FsrC, an SHK from the Gram-positive Enterobacter 
faecalis that is found in the human gut. Vancomycin-resistant E. faecalis (VRE) has recently become 
a severe clinical problem.11 Gelatinase biosynthesis-activating pheromone (GBAP), a small cyclic 
lactone-containing peptide, has been shown to be the cognate ligand of FsrC.12 In order to find an 
appropriate inhibitor, actinomycete culture supernatants were screened, resulting in the discovery of 
Siamycin I, which suppressed GBAP-based signal transduction by FsrC.13-14 In addition, the AgrC-
AIP (autoinducing peptide) pairs from Staphylococcus aureus can be divided into four agr specificity 
groups. On the same SHK, non-cognate AIPs work antagonistically against the cognate ligands. 
These results demonstrate the feasibility of finding small molecules that inhibit responses to 
physiological stimuli.15 These virulence-attenuating compounds, which we term Class I compounds, 
can be discovered within pre-existing libraries of small molecules.  
The second mechanism of TCS targeting involves direct inhibition of signal output from 
essential SHKs. An example target would be the WalK SHK, which has been shown to be essential 
in several Gram-positive species.16 Several inhibitors of WalK have been previously identified by 
complementary screening methods involving synthetic libraries and cell lysates.17-19 In these cases, 
an example of what we call Class II compounds have shown to have specific interaction with WalK 
that lead to cell death in Bacillus subtilis and Staphylococcus aureus. In a similar manner, HP0165 
of Helicobacter pylori
 
and MtrB of Mycobacterium tuberculosis
 
are also essential for cell viability 
and could be targeted in a similar manner.20-21 
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We propose a modular screening platform that can rapidly test libraries of small molecules to 
facilitate identification of inhibitors of stimulus perception (Class I) or compounds that directly 
inhibit signal output from essential SHKs (Class II). In addition, we propose that this platform can be 
used to identify natural or artificial stimulatory ligands for SHKs that are involved in virulence. The 
central idea is that the periplasmic domain of the SHK of interest is fused to the platform that 
comprises the cytoplasmic domain of a well-characterized SHK, which in turn governs fluorescent 
reporter genes for a fast, reliable and detectable signal. In this study, we have physically coupled the 
periplasmic stimulus-perceiving domains from bacterial receptors (chemoreceptors or SHKs) to the 
cytoplasmic domain from the major osmosensor of E. coli (EnvZ), which is part of a well-
characterized signaling pathway. This approach allowed us to directly couple stimulus-perception by 
the periplasmic domain of the aspartate chemoreceptor (Tar) from E. coli to an EnvZ-based signaling 
pathway that controls transcription of cyan fluorescent protein (CFP) and yellow fluorescent protein 
(YFP). This synthetic circuit facilitated detection of changes in chimeric signal output by monitoring 
whole-cell CFP and YFP fluorescence by spectrofluorometery or on a single-cell level by flow 
cytometry. We also employed aromatic tuning22-23 to modulate the signal output of two different Tar-
EnvZ (Taz1 and Tez1A1) chimeras. In some cases, this tuning resulted in a change in baseline signal 
output while retaining the sensitivity to aspartate. The value of aromatic tuning became evident when 
we created a novel chimera composed of the periplasmic domain of the nitrate/nitrite sensor of E. coli 
(NarX) and the cytoplasmic domain of EnvZ, which possessed no signal output until aromatic tuning 
was employed. We would like to emphasize that the screening platform is optimized for automated 
flow cytometry, which can facilitate rapid screening of pre-existing compound libraries for novel 
signal-modulating compounds that possess antibacterial properties. 
Results and Discussion 
 
Re-creation of two Tar-EnvZ chimeras (Taz1 and Tez1A1) 
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TCSs must detect a wide variety of stimuli in order to control of a diverse array of bacterial 
processes. Within an evolutionary context, this has been accomplished by altering the stimulus-
sensing properties of the periplasmic domains of SHKs and the DNA-binding specificity of RR output 
domains, while leaving the remainder of the TCS scaffold fundamentally unchanged (Figure 1A). 
Within canonical homodimeric SHKs, a common membrane-spanning topology is observed that 
consists of a cytoplasmic N-terminus, the first transmembrane helix (TM1), a periplasmic stimulus-
perceiving domain, the second transmembrane helix (TM2), the cytoplasmic dimerization and 
histidyl phosphotransfer domain (DHp), and the C-terminal catalytic ATPase (CA) domain (Figure 
1B). The modular screening platform presented here exploits the conservation observed within the 
TM and HAMP (originally identified within histidine kinases, adenylate cyclases, MAP kinases and 
phosphatases) domains to physically couple periplasmic stimulus-perceiving domains from targeted 
SHKs to cytoplasmic domains with well-characterized signaling pathways to produce chimeric 
SHKs. This allowed us to directly couple stimulus-perception to stimulation of a well-characterized 
EnvZ-based signaling pathway.24-27  
We began by generating previously described functional chimeric receptors containing the 
periplasmic and transmembrane domains of the aspartate chemoreceptor (Tar) and the cytoplasmic 
signaling domains of the major osmosensor of E. coli (EnvZ, Figures 2A and 2B).28-29 An additional 
advantage to this system is that the cytoplasmic domain of EnvZ (EnvZc) has been previously shown 
to be sufficient for osmosensing.30-32 Therefore, we can easily determine whether the osmosensing 
functionality can be retained in chimeras possessing a periplasmic domain that sense a stimulus not 
directly related to osmosensing. 
 The fusion point of the chimeric Taz1 receptor is located near the C-terminus of the HAMP 
domain, resulting in both transmembrane helices (TM1 and TM2) and the majority of the HAMP 
domain being contributed from Tar, while the remainder of the chimera is from EnvZ.28 Tez1A1 is 
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similar to Taz1, except that the fusion point is not within the HAMP domain but rather at the 
cytoplasmic end of TM2.29 To restore functional coupling between Tar and EnvZ within Tez1A1, an 
additional alanine residue (Ala-213) was introduced immediately C-terminal to the final residue 
contributed by Tar (Ile-212).29 Consequently, the two transmembrane helices of the receptor are 
supplied by Tar, while the entire cytoplasmic domain originates from EnvZ (Figures 2A and 2B). It 
should also be noted that we added a short C-terminal heptaresidue linker and V5-epitope tag in order 
to assess expression levels. We have previously shown that this tag does not alter the signal output 
from wild-type EnvZ.22 
 
Modulation of signal output from Taz1 and Tez1A1 in response to osmolarity and aspartate 
 
MDG147 is a dual-color fluorescent reporter strain that has been previously used to quantify 
transcription regulated by the EnvZ/OmpR TCS. The strain is a derivative of K-12 MG1655 that 
possesses transcriptional fusions of cfp to ompC and of yfp to ompF.33 Therefore, the level of 
intracellular phosphorylated OmpR can be estimated by quantifying the ratio of CFP to YFP 
fluorescence (Figure S1A). As previously described, MDG147/pEB5 cells demonstrated elevated 
levels of EnvZ signal output as measured by CFP/YFP ratio when cells were grown under the high 
osmolarioty regime (15% sucrose) compared to when grown under the low osmolarity regime (0% 
sucrose) (Figures S1B and S1C).22, 33-34 Strain EPB3035 is a envZ derivative of MDG147 that is 
suitable for assessing the signal output upon plasmid-based expression of the tar-envZ genes. A band 
was observed that represented the Tar-EnvZ chimera from EPB30/pRD500 and EPB30/pRD501 cells 
expressing Taz1 or Tez1A1 respectively, whereas control strains not expressing the V5-tagged EnvZ 
did not produce this band (Figure S2). These bands demonstrate that the chimeras are stably expressed 
and suitable for subsequent analysis.  
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We continued by measuring the relative signal output from EnvZ-deficient circuits containing 
either Taz1 or Tez1A1. This was accomplished by comparing CFP and YFP fluorescence from cells 
expressing Taz1 (EPB30/pRD500) or Tez1A1 (EPB30/pRD501) with fluorescence from cells 
expressing wild-type EnvZ (MDG147/pEB5) or envZ cells (EPB30/pEB5). We determined that 
circuits containing either Tar-EnvZ chimera exhibited CFP and YFP levels greater than envZ cells. 
This demonstrates that the chimeras were able to phosphorylate OmpR in the absence of aspartate, 
the cognate ligand for the Tar periplasmic domain. Furthermore, a change in CFP/YFP ratio was 
observed when these cells were grown under the high-osmolarity regime, albeit to a smaller degree 
than wild-type cells (Figure S3). Thus, external osmolarity appears to modulate signal output from 
both Tar-EnvZ chimeras, which confirms previous results suggesting that external osmolarity is 
sensed and processed by the cytoplasmic domain of EnvZ.30-31 
To examine response to aspartate, EPB30/pRD500 or EPB30/pRD501 cells expressing Taz1 
or Tez1A1, respectively, were subjected to increasing concentrations of aspartate. For both receptors, 
we observed an increase in CFP fluorescence (Figure S4A), a decrease in YFP fluorescence (Figure 
S4B) and an overall increase in the CFP/YFP ratio (Figure 3A). Leucine or isoleucine, present at 10 
mM as controls, showed minimal effect on signal output from these circuits (Figure 3A). It should be 
noted that this result is in disagreement with previously published data demonstrating that leucine 
decreases Taz1 signal output.36 In addition, the CFP/YFP ratio curves are parallel for both Tar-EnvZ 
chimeras, indicating that they responded to aspartate in a similar manner, although Tez1A1 possessed 
a slightly elevated signal output across the entire curve. When the increase from baseline was 
calculated, circuits containing Taz1 possessed a greater dynamic range (about a 30-fold increase in 
CFP/YFP ratio) compared to those containing Tez1A1 (about a five-fold increase in CFP/YFP ratio). 
These results clearly demonstrate the value in producing chimeras with minimal baseline signal 
output in applications requiring detection of an increase in CFP/YFP ratio due to stimulus-perception 
(Figure 3B). In circuits containing Tez1A1, it appears that CFP fluorescence becomes saturated, an 
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effect that limits the overall dynamic range of circuits containing this chimera (Figure S4). In 
summary, these results indicate that both Taz1 and Tez1A1 respond to aspartate and demonstrate that 
our synthetic circuits with Tar-EnvZ chimeras function as expected based on previous results. 
 
Aromatic tuning of Taz1 and Tez1A1 
 
As shown in Figure 3, not only is it necessary to design chimeras in which the stimulus-
perceiving domain is functionally coupled to the intracellular signaling domains; it is also important 
to ensure that the baseline signal output is appropriate for the desired application, which means that 
the fluorescent output of the reporter proteins does not saturate. For example, when screening a 
compound library for small molecules that inhibit stimulus-perception (Class I), it is advantageous to 
use chimeras that possess a low baseline signal output that significantly increases upon addition of 
the cognate stimulus. In this regard, Figure 3 clearly demonstrates that using Taz1 is superior to 
Tez1A1 within a synthetic circuit. This parameter comes into play within a screening platform that 
aims to detect Class I compounds that prevent perception of aspartate by the periplasmic domain of 
the Tar-EnvZ chimeras. Conversely, when screening for Class II small molecules that inhibit signal 
output from an essential SHK, a higher baseline signal output would be favorable as a decrease of 
signal output upon binding of the inhibitor must be detectable. In addition, when screening for natural 
or artificial ligands of SHKs involved in virulence, it would be critical to have a low baseline signal 
output. 
Based on the “regulated unfolding” model of signal transduction37, which proposes that 
signaling within a receptor is guided by unfolding of individual receptor subdomains, the TM2–
HAMP junction (Figure 1B) is an ideal position to target with the aim of mimicking signal 
transduction due to stimulus-perception. We have shown that moving aromatic residues about their 
original position, by site-directed mutagenesis, at the C-terminal end of TM2 and adjacent to the 
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TM2-HAMP interface, modulates signal output from the aspartate chemoreceptor of E. coli (Tar)
 
and 
from full-length EnvZ22-23, 38. In order to manipulate baseline signal output, we examined whether 
aromatic tuning could be employed within the context of the Tar-EnvZ chimeras. Taz1 and Tez1A1 
were modified by repositioning a Trp-Tyr tandem pair about its original position at the cytoplasmic 
end of the TM2 domain of Tar (Figure 4A).38 We began by expressing the tuned chimeras from 
pRD500 (Taz1) and pRD501 (Tez1A1), respectively, in EPB30 cells and monitored their expression. 
When EPB30 cells were grown under the low-osmolarity regime, we found that the WY-3 and WY+1 
variants of Taz1 and the WY+1 variant of Tez1A1 were unstable (Figures S5A and S5B). When the 
EPB30 cells were grown under the high-osmolarity regime, only the WY+1 variants of Taz1 and 
Tez1A1 were unstable. Thus, the WY-3 variant of Taz1 was differentially stable based upon the 
growth regime that was employed. In addition, the degradation appeared to be a two-step process 
(Figure S5C). Receptors that exhibited degradation, e.g. Taz1 WY-3, Taz1 WY+1 and Tez1A1 
WY+1, were not analyzed further. 
We observed that aromatic tuning modified signal output from the chimeras, as evidenced by 
a change in steady-state signal output (Figure 4B, CFP/YFP ratio). As seen with full-length EnvZ,22 
the pattern of signal outputs from EPB30/pRD500 cells expressing the tuned variants of Taz1 follows 
a helical pattern, suggesting that the TM2 surface that the aromatic residues reside upon is of critical 
importance (Figures 4B and S6). A possible explanation for this observation is that the rotational 
movement of the aromatic residues around the TM2 surface results in disruptions to the helical 
packing of the transmembrane domain as proposed previously within EnvZ.22 For example, the WY-
2 and WY+2 variants represent local signal output maxima, whereas WY-1 and WY+3 possess lower 
signal output, and the wild-type results in the lowest fluorescent output. Also consistent with these 
results are the observations the WY-3 and WY+1 variants were subject to degradation (Figure S5), 
an effect that may reflect disorder in the packing of TM2.  
The results with cells expressing the tuned variants of Tez1A1 were similar, but the entire set 
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possessed greater levels of signal output compared to their Taz1 counterparts (Figure 4B). In most 
cases, the dynamic range of the aromatically tuned chimeras in response to external osmolarity were 
similar, with a four-fold to five-fold increase in CFP/YFP ratio for the Taz1 family and between a 
two-fold and four-fold increase for the Tez1A1 family (Figure 4C). As shown in Figure S6, the 
changes in CFP/YFP ratio were due to both an increase in CFP fluorescence and a concomitant 
decrease in YFP fluorescence. The notable exception was the wild-type Taz1, which showed a smaller 
dynamic range than the other tuned Taz1-containing circuits, likely because the extremely low CFP 
fluorescence values obscure any real differences in the signal (Figure S6). 
 
Response of the aromatically tuned Taz1 and Tez1A1 chimeras to aspartate  
 
 We expressed the aromatically tuned Taz1 and Tez1A1 variants in EPB30/pRD500 or 
EPB30/pRD501 cells, respectively, and monitored changes in signal output in response to increasing 
concentrations of aspartate. In all cases, the surface that the aromatic residues reside upon governed 
signal output. For the Taz1 family of tuned chimeras, the wild-type Taz1 and the WY+3 variants 
exhibited the greatest increases in signal output, as measured in fold-change in CFP/YFP ratio. The 
next most responsive to aspartate were the WY-1 and WY+2 variants, which also reside on the same 
helical surface, whereas WY-2 did not demonstrate an increase. It is also important to note that two 
chimeras that were subject to degradation (Taz1 WY-3 and WY+1) also reside on the same surface 
of TM2 (Figures 5 and S7). Assessing the family as a whole, an inverse correlation was observed 
between steady-state signal output and the magnitude of response to aspartate. In other words, the 
lower the steady-state CFP/YFP signal output, the greater the increase in signal output in response to 
increasing aspartate concentrations (Figures 5 and S7).  
 The aromatically tuned variants of Tez1A1 behaved differently than the Taz1-based family in 
response to saturating aspartate. The minus variants (WY-3 through WY-1) were all stable and 
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strongly activated, as shown by elevated CFP levels (Figure S7), reduced YFP levels (Figure S7) and 
high CFP/YFP ratios (Figure 5). The WY+1 variant was subject to cleavage, whereas the unmodified 
Tez1A1 and the WY+2 and WY+3 variants responded to aspartate (Figures 5 and S7).  
In order to test the applicability of this platform for high-throughput screening, we compared 
the results of this experiment with experiments performed with flow cytometery. Besides a drastically 
improved throughput, flow cytometry also provides an additional level of resolution, allowing the 
fluorescent signal from single cells rather than entire populations to be observed. For the tuned Taz1 
and Tez1A1 families, we observed similar relative baseline signal output (CFP/YFP ratio) and 
response to saturating aspartate concentrations (medium gray). Isoleucine at 10 mM (white) was 
employed as a control and showed comparable ratios to baseline activity (dark gray; Figure 6). Both 
methodologies show a significant (p < 0.001) increase in signal output from several receptors upon 
addition of aspartate. This result demonstrates that analysis via automated flow cytometry is a viable 
method for high-throughput screening (Figure 6). 
 
Creation and analysis of tuned NarX-EnvZ (NavZ1) chimeras 
 
 In order to demonstrate that the aforementioned methods were not restricted to the Tar-EnvZ 
chimeras, we created a novel protein, which we termed NavZ1, that contains the periplasmic sensor, 
transmembrane domains and of HAMP domain of the nitrate/nitrite sensor of E. coli (NarX) fused to 
the cytoplasmic signaling domain of the sensor histidine kinase EnvZ. The fusion joint was within 
the HAMP domain and in the same relative position as the fusion joint in Taz1 (Figures 7A and 7B). 
A catatg (His-Met) NdeI restriction site was introduced at the C-terminal end of the NarX fragment 
to create the fusion point at the same location as in the Tar-EnvZ chimeras. Expression of Naz1 from 
pRD502 in EPB30 cells demonstrated the presence of intact NavZ1 (Figure S8). However, the 
unstimulated fluorescence signal of CFP and YFP was lower than that of EPB30/pEB5 (envZ) cells, 
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showing that signal output was insufficient to generate enough phospho-OmpR to result in ompF and 
yfp transcription (Figure 7C). Thus, we did not further analyze the un-tuned NavZ1. 
To assess whether aromatic tuning can restore activity, we moved the NarX-derived Trp-173 
residue of NavZ1 about its original position near the cytoplasmic end of TM2, resulting in the W-3 
through W+3 variants (Figure 7D). Unlike Taz1 and Tez1A1, all aromatically tuned variants were 
expressed stably (Figure S8), and all of them, when expressed in EPB30/pRD502 (NavZ1) cells, 
supported higher levels of CFP or YFP fluorescence than EPB30/pEB5 (envZ). Thus, aromatic 
tuning can restore the activity of a non-functional chimera.  
The minus-series of NavZ1 variants, W-3 through W-1, produced YFP fluorescence similar 
to cells expressing Taz1, while the plus-series of mutants, W+1 through W+3, exhibited even higher 
signal output than the minus-series. In addition, osmolarity modulated signal output from all NavZ1 
chimeras that were analyzed (Figures 7E and S9). It should also be noted that local minima/maxima 
were observed as the Trp residue was repositioned around the surface of TM2. 
 Several lines of research have demonstrated that when aspartate binds to Tar, a displacement 
of TM2 on the order of 1-3 Å toward the cytoplasm occurs. 38-45 The final result is a decrease in CheA 
kinase activity that leads to counterclockwise (CCW) flagellar rotation, which constitutes an 
attractant response.46-49 In contrast, previous analyses of a NarX-Tar chimera, demonstrated that 
nitrate elicits clockwise (CW) flagellar rotation, which is indicative of a repellent response.50-51 
Consistent with this observation, crystallographic structures of the periplasmic domain of NarX 
demonstrate a relative displacement between the N- and C-terminal helices (helices 1 and 4) of the 
NarX sesnsor domain that is opposite of the one observed in the crystallographic structure of the 
periplasmic of Tar.43, 52 Based on these results, we predicted a reduction in NavZ1 signal output upon 
addition of nitrate, rather than the increases observed with Taz1 and Tez1A1 after addition of 
aspartate. 
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 As described above, it is important for tuned chimeric receptors to possess signal output 
appropriate for the assay to be performed. Therefore, we predicted that observation of a decrease in 
signal output of NavZ1 would require a high-steady state fluorescence signal. The W-3, W-2, W-1, 
wild-type and W+2 NavZ1 variants did not fulfill this requirement. 
For this application, we employed automated flow cytometry because adding 10 mM KNO3 
dramatically increased the growth rate of EPB30/pRD502 (NavZ1) cells relative to cultures 
containing 10 mM KCl, thus casting doubt on the reliability of experiments using spectrophotometry 
with bulk cultures. This problem is less of a concern during flow cytometric analysis. The steady-
state signal output from unstimulated cells analyzed by spectrophotometry (MMA; Figure 8A) was 
found to be similar across the family of tuned variants when compared to those analyzed by flow 
cytometry (MMA; Figure 8B). These results gave us confidence in the usage of flow cytometry for 
analysis of signal output by the NavZ1 chimeras. When 10 mM KNO3 was used as the cognate ligand, 
we observed a significant (p < 0.001) decrease in signal output from the tuned W+1 variant (Figure 
8B), while the W+3 variant did not exhibit such a decrease, giving us confidence that the decrease in 
signal output with the W+1 receptor was due to decreased signaling rather than a pleiotropic effect 
on cell metabolism. These results demonstrate that a stable NarX-EnvZ chimera can be created and 
that aromatic tuning can restore fluorescence signal output and generate receptors (W+1 in this case) 
that are useful for monitoring changes in response to stimuli. 
 
Summary and concluding remarks 
 
In summary, the majority of the aromatically tuned Tar-EnvZ receptors were stably expressed 
and responded to aspartate to an extent that correlates inversely with their baseline signal output. We 
found that the fusion site of Taz1, which is within the C-terminus of the HAMP domain, is more 
amenable for the rational chimera design than that site employed within Tez1A1, which is 
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immediately C-terminal to TM2. This result suggests that it may be important to have both TM2 and 
the HAMP domain contributed by the receptor to be tested. This is finding is reasonable, as direct 
communication between TM2 and HAMP has been shown to be important for the signaling properties 
of chemoreceptors.53-55 We also showed that we could, through aromatic tuning, generate a NarX-
EnvZ chimera that responded to the addition of nitrate, the most effective ligand for NarX. Finally, 
we showed that flow cytometry should be applicable to the screening of large libraries of possible 
ligands, whether agonistic or antagonistic, for any given receptor. 
Two previously studied Tar-EnvZ chimeras (Taz1 and Tez1A1) were functional within our 
experimental platform as measured by population-level microplate fluorometry and flow cytometry 
on a single-cell level. Both chimeras were expressed, embedded within the membrane and mediate 
response to aspartate. Aromatic tuning was employed within the chimeras with varying success, as 
different tuned chimeras had various initial steady-state signal outputs. An inverse correlation was 
observed between the extent of baseline signal output and the degree of response to aspartate. Finally, 
we created a novel NarX-EnvZ (NavZ1) chimera that could be aromatically tuned to restore signal 
output to a non-functional chimera while responding to stimulus. A recent paper demonstrated 
production of function and non-functional chimeric chemoreceptors with different fusion points.56 
We believe that employment of aromatic tuning as described here would restore signal output to the 
non-functional chimeras.  
We propose that strain EPB30 and plasmid-based chimeric receptor expression from a suitable 
derivative of pRD500 can be employed as a modular high-throughput screening platform. In the case 
of Class I SHK targets, we have shown with the tuned Taz1 and Tez1A1 chimeras that a minimal 
baseline signal output is desirable, such that the cognate ligand facilitates the greatest dynamic range 
possible. This situation maximizes the ability of these synthetic circuits to respond to inhibition of 
their activity by a relevant stimulus and allows us to identity such perception-inhibiting compounds. 
A recent review nicely summarizes virulence-attenuation involving what we term Class I SHK 
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targets.57 With Class II SHK targets, it was shown to be critical to have the maximal possible signal 
output so that even a small decrease could be observed during screening. We propose that such a 
platform could be employed to identify novel compounds that interact with the targeted periplasmic 
domain. It is important to note that aromatic tuning resurrected the “dead” NavZ1 chimera to allow 
nitrate to be identified as significantly decreasing (25%, p < 0.001) signal output. 
 In conclusion, the work described here introduces a modular platform that is amenable to 
interchangable periplasmic domains and screening libraries of small molecules. We propose that this 
platform has several advantages over previous screening methods. Firstly, it will facilitate direct 
identification of compound:SHK pairs due to a single chimera governing transcription of ompC and 
ompF, and thus CFP and YFP fluorescence, of which changes can be easily identified. This is major 
advantage compared to standard in vivo screening that requires expensive and time-consuming 
subsequent target validation. Second, in the long-term, this platform will allow targets, namely SHKs 
from multidrug resistant (MDR) organisms, to be screened in non-pathogenic laboratory strains such 
as E. coli EPB30. This ability will greatly expand the spectrum of research groups that can participate 
in antibacterial screening by reducing the initial requirement for ACDP Category 3 or 4 facilities. In 
addition, it makes targeting SHKs from an organism solely based on its annotated genome sequence 
possible. Third, the platform only screens molecules that interact only with the periplasmic domain 
of the SHK that is fused to EnvZ, which eliminates the necessity for exogenous compounds to cross 
the cytoplasmic membrane. Finally, the ability to employ one method on a wide range of targets 
would standardize screening results, with the resulting benefit of being able to compare results for an 
entire family of related SHKs or with libraries of related compounds from a library of small 
molecules. 
 
Methods 
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Bacterial strains and plasmids 
 
 For all DNA manipulations, E. coli strain MC106158 was used. To control for light scattering 
and cellular autofluorescence during population-based measurements, strain MG1655 was employed. 
Strains MDG147 [MG1655 (ompF+-yfp+) (ompC+-cfp+)]33 and EPB30 (MDG147 envZ::kan)35 
were used for analysis of steady-state signal output in measurements at both the population and 
single-cell levels. Plasmids used for chimeric receptor expression were derived from pRD40022 in 
order to retain the same IPTG-based induction of receptor expression. Initially, the N-terminal section 
of Tar was amplified from pMK113V539 in a manner that facilitated subcloning of residues Met-1 
through His-243, which resulted in pRD500 that expresses Taz1-V5 upon induction with IPTG. It 
was previously shown that the V5-eiptope tag has no adverse effect on EnvZ or Tar signal output.22, 
34, 39, 55, 59-61 Standard site-directed mutagenesis techniques were employed to move the Trp-Tyr pair 
about their original position. A USER-based cloning method62-63 was used to create pRD501 from 
which Tez1A1 was expressed. The advantage of the method is that the aromatic tuning and the 
addition of the Ala after the end of TM2 were created simultaneously. Finally, standard molecular 
biological methods were employed to amplify the narX gene from strain BW25113 and subclone 
residues Met-1 through Asn-217 into pRD500. This required a N218H substitution within the NarX 
component in order to create an NdeI resturction site for molecular cloning. The final product, 
pRD502, expresses NavZ1 upon induction with IPTG in a similar manner to the above chimeras. 
Site-directed mutagenesis was carried out as above to aromatically tune (Trp-173) the NarX-EnvZ 
chimera. A previously described plasmid, pEB564 served as an empty vector control that did not 
express envZ. 
 
Population-based analysis of signal output  
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Analysis was performed as described previously22, 64 with slight modification. Fresh colonies 
of MDG14733 or EPB3035 transformed with pEB564, pRD500 (Taz1), pRD501 (Tez1A1) or pRD502 
(NavZ1) as necessary were used to start 2-ml overnight culture of minimal medium A65 supplemented 
with 0.2% glucose, 50 g/ml ampicillin and 20 m IPTG. When cells were grown under the high 
osmolarity regime, 15% sucrose was present. Aspartate, leucine or isoleucine was present as 
indicated. After growing overnight at 37 ºC, cells were diluted at least 1:1000 into 7 ml of fresh 
medium. When cultures reached an OD600nm ~ 0.3, chloramphenicol was added to a final 
concentration of 170 μg/ml to fully inhibit protein synthesis. 2 ml of culture was immediately used 
for analysis in a Varian Cary Eclipse spectrofluorometer (Palo Alto, CA), while the remainder was 
centrifuged and store at -80 ºC for immunoblotting. CFP fluorescence was measured using an 
excitation wavelength of 434 nm and an emission wavelength of 477 nm, while YFP fluorescence 
was measured by using an excitation wavelength of 505 nm and an emission wavelength of 527 nm. 
Differences in cell density were corrected for by dividing the fluorescence intensities by the OD600nm 
of each culture. These values were also corrected for autofluorescnce as observed from 
MG1655/pEB5 cells. 
 
Single-cell analysis of signal output 
  
Cells were grown in a similar manner to those used for population-based analysis with slight 
modifications. As described above, cells were grown overnight at 37 ºC and diluted at least 1:1000 
into 3.5 ml of fresh medium with cognate ligand (aspartate or potassium nitrate), control (leucine, 
isoleucine or potassium chloride) as appropriate. After dilution, cultures were measured directly by 
flow cytometry (Life Technologies Attune) using a violet (405 nm) and blue (488 nm) laser 
configuration with detection at 430-470 nm and 515-545 nm respectively. A minimum of 50,000 
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events for each independent culture were recorded. Compensation was performed by employing 
strains expressing only CFP or YFP. 
 
Assessing expression of the V5-tagged chimeras 
  
EPB30 cells expressing a chimeric receptor from pRD500 (Taz1), pRD501 (Tez1A1) or 
pRD502 (NavZ1) were grown as described above to an OD600nm ~ 0.3, harvested by centrifugation 
and resuspended in 50 l 6X SDS-PAGE sample buffer. Resuspended pellets were subjected to three 
freeze-thaw cycles of 10 minutes each and then electrophoresed on a 12% SDS/acrylamide gel. 
Subsequently, standard conditions were employed for electrophoresis and immunoblotting66. During 
immunoblotting, anti-V5 (Invitrogen) and anti--lactamase (Abcam) were employed as primary 
antibodies, while Peroxidase-conjugated anti-mouse IgG (Sigma) was used as the secondary 
antibody. Visulaization and acquisition of the bands was accomplished with ECL Advance Western 
Blotting Detection Kit (GE Healthcare), a Lumi-Imager F1 Workstation (Roche) and Image Gauge 
v4.22 software (Fujifilm). 
 
Statistical analysis 
 
All statistical analysis including the one-way ANOVA tests with Tukey-HSD post-hoc 
analysis were performed using IBM SPSS v23 statistics software (IBM, Armonk, NY, USA). Three 
asterisks indicate a p-value of less than 0.001.  
 
Supporting information 
 
Various control experiments described throughout the text have been provided (Figures S1−S3, S5 
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and S8). Additional information about the fluorescent output from circuits containing Tar-EnvZ 
chimeras in the absence (Figures S4 and S6) or presence of aspartate (Figure S7) are also provided. 
Finally, additional information about the fluorescence output from circuits containing NarX-EnvZ 
chimeras is shown (Figure S9). This material is available free of charge via the Internet at 
http://pubs.acs.org.  
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minimal medium A; ACDP, advisory committee on dangerous pathogens; PCR, polymerase chain 
reaction; ECL, enhanced chemiluminescence. 
 
 
Figure legends 
 
Figure 1. Harnessing the modularity of TCSs to create chimeric SHKs. (A) Upon stimulus perception 
by the sensor domain (white) of a canonical SHK, the kinase activity of the CA domain (gray) 
increases. This results in phosphorylation of the conserved histidyl residue within the DHp domain. 
Phosphoryl groups are transferred to the aspartyl residue within the received domain of the RR, which 
usually increases DNA-binding activity of the output domain (black). (B) Canonical SHKs are usually 
homodimeric and consist of a cytoplasmic (cyto) N-terminus, first transmembrane (TM) helix, a large 
periplasmic (peri) sensor domain, the second transmembrane helix, the dimerization / 
histidylphosphotransfer domain (DHp) and the catalytic ATPase (CA) domain. Some SHKs contain 
additional domains between TM and DHp including HAMP domains. We will exploit conservation 
within the TM and HAMP domains (depicted in red) to create chimeric SHKs. 
 
Figure 2. Linear and topological composition of the Taz1 and Tez1A1 chimeras. (A) Taz1 is 
composed of the N-terminus of Tar (white) and the C-terminus of EnvZ (gray) with a fusion joint 
near the C-terminus of the HAMP domain. Tez1A1 is similar but contains the HAMP domain of 
EnvZ. Tez1A1 also requires addition of an Ala residue to TM2 for functionality. The purple box 
indicates the site of aromatic tuning, with the Trp-Tyr tandem responsible for modulation of signal 
output is highlighted. (B) Topological composition of the Taz1 and Tez1A1 chimeras is the same as 
in Figure 1B. The location of aromatic tuning and the additional Ala residue required within Tez1A1 
are also depicted. 
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Figure 3. Response of circuits containing Taz1 or Tez1A1 to aspartate. (A) EPB30 cells expressing 
Taz1 (circles) or Tez1A1 (triangles) demonstrate an increase in signal output (CFP/YFP) due to 
increasing aspartate. Leucine (Leu) or isoleucine (Ile) present at 10 mM (gray line) had minimal effect 
on signal output from either chimera. (B) Fold change from baseline levels of CFP/YFP. Circuits 
containing Taz1 show an increase in signal output of roughly 30-fold, whereas those expressing 
Tez1A1 show an increase of only 5-fold, presumably because of higher baseline signal output. 
Addition of leucine (Leu) or isoleucine (Ile) at 10 mM (gray line) had minimal effect on signal output 
from either chimera. Error bars represent standard error of the mean with a sample size of n ≥ 3. 
 
Figure 4. Signal output from circuits containing the aromatically tuned variants of Taz1 and Tez1A1. 
(A) The primary amino acid sequence where the aromatic tuning was undertaken. The residues 
contributed by Tar are colored in black, the Trp-Tyr tandem being repositioned is presented in red, 
and residues contributed by EnvZ are shown in white with a black background. (B) Steady-state signal 
output of the aromatically tuned Taz1 (circles) or Tez1A1 (triangles) chimeras expressed in EPB30 
cells grown under the low- (0% sucrose, empty) or high-osmolarity (15% sucrose, filled) regime. 
Chimeras that exhibited degradation in Figure S5 were not examined. (C) Dynamic range of the 
various circuits containing the aromatically tuned Taz1 and Tez1A1 chimeras. Error bars represent 
standard error of the mean with a sample size of n ≥ 3. 
 
Figure 5. Response to aspartate from circuits containing the aromatically tuned variants of Taz1 or 
Tez1A1. (A) Changes in signal output (CFP/YFP) from EPB30 cells expressing one of the tuned 
Taz1 variants (circles, WY-2; triangles, WY-1; squares, wild-type; diamonds, WY+2; pentagons, 
WY+3) (B) Changes in signal output (CFP/YFP) from EPB30 cells expressing one of the tuned 
Tez1A1 variants (stars, WY-3; circles, WY-2; triangles, WY-1; squares, wild-type; diamonds, 
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WY+2; pentagons, WY+3). (C) Fold change from baseline CFP/YFP in EPB30 cells expressing the 
wild-type and tuned Taz1 variants. (D) Fold changes from baseline CFP/YFP in EPB30 cells 
expressing the wild-type and tuned Tez1A1 variants. Error bars represent standard error of the mean 
with a sample size of n ≥ 3. 
 
Figure 6. Single-cell analysis of signal output from the tuned Tar-EnvZ chimeras. (A) Response of 
EPB30/pRD500 (Taz1) cells to no additional ligand (dark gray; MMA), 10 mM aspartate (medium 
grey; ASP) or 10 mM isoleucine (white; ILE) as analyzed by population-based average in a 
spectrofluorometer (left panel) or at a single-cell level in a flow cytometer (right panel). (B) Response 
of EPB30/pRD501 (Tez1A1) cells to no additional ligand (dark gray; MMA), saturating aspartate 
(medium gray; ASP) or saturating isoleucine (white; ILE) as analyzed by population-based average 
in a spectrofluorometer (left panel) or at a single-cell level in a flow cytometer (right panel). Error 
bars represent standard error of the mean with a sample size of n ≥ 3. To determine statistical 
significance, one-way ANOVAs with Tukey’s HSD post hoc analysis were performed. Three 
asterisks indicate a p-value of less than 0.001.  
 
Figure 7. Creation and analysis of the NarX-EnvZ chimeras. (A) Linear composition of the NavZ1 
chimera. NavZ1 is composed of the N-terminus of NarX (white) and the C-terminus of EnvZ (gray) 
with a fusion point near the C-terminus of the HAMP domain. NavZ1 requires substitution of a His 
residue within the HAMP domain to create an NdeI restriction site. The purple box indicates the site 
of aromatic tuning, with the Trp residue responsible for modulation of signal output underlined. (B) 
Topological composition of the NavZ1 chimera with the same color scheme and notation as above. 
(C) CFP and YFP fluorescence from circuits expressing the wild-type or one of the tuned NavZ1 
variants. EPB30/pRD502 cells expressing the wild-type NavZ1 exhibited almost no detectable CFP 
or YFP fluorescence. Dashed lines representing CFP and YFP levels from EPB30/pEB5 (envZ) cells 
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are provided. (D) The primary sequence where the aromatic tuning is being undertaken. The Trp 
residue is shown in red and underlined. (E) Steady-state signal output of aromatically tuned NavZ1 
chimeras grown under the low- (0% sucrose, empty circles) or high-osmolarity (15% sucrose, filled 
circles) regime. Error bars represent standard error of the mean with a sample size of n ≥ 3. 
 
Figure 8. Analysis of signal output and ligand-response from tuned NavZ1 chimeras. (A) Steady-
state signal output from EPB30/pRD502 (NavZ1) cells grown under the low-osmolarity regime (gray; 
MMA) and analyzed by spectrofluorometry. (B) Response to no ligand (gray; MMA), 10 mM 
potassium nitrate (lighter grey; KNO3) or 10 mM potassium chloride (white; KCl) as analyzed at 
single-cell level by automated flow cytometry. Error bars represent standard error of the mean with 
a sample size of n ≥ 3. To determine statistical significance, one-way ANOVAs with Tukey’s HSD 
post hoc analysis were performed. Three asterisks indicate a p-value of less than 0.001.  
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Figure S2. 
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Figure S3. 
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Figure S4. 
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Figure S5. 
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Figure S6. 
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Figure S7. 
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Figure S8. 
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Figure S9. 
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